These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8921825)

  • 1. Effects of gonadotropin-releasing hormone on bioactivity of follicle-stimulating hormone (FSH) and microstructure of FSH, luteinizing hormone and sex hormone-binding globulin in a testosterone-based contraceptive trial: evaluation of responders and non-responders.
    Simoni M; Peters J; Behre HM; Kliesch S; Leifke E; Nieschlag E
    Eur J Endocrinol; 1996 Oct; 135(4):433-9. PubMed ID: 8921825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D; Smith S; Zacur H
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis.
    Zwart AD; Urban RJ; Odell WD; Veldhuis JD
    Eur J Endocrinol; 1996 Oct; 135(4):399-406. PubMed ID: 8921820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulsatile administration of gonadotropin-releasing hormone does not alter the follicle-stimulating hormone (FSH) isoform distribution pattern of pituitary or circulating FSH in nutritionally growth-restricted ovariectomized lambs.
    Hassing JM; Kletter GB; I'Anson H; Wood RI; Beitins IZ; Foster DL; Padmanabhan V
    Endocrinology; 1993 Apr; 132(4):1527-36. PubMed ID: 8462450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men.
    Castro-Fernández C; Olivares A; Söderlund D; López-Alvarenga JC; Zambrano E; Veldhuis JD; Ulloa-Aguirre A; Méndez JP
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4603-10. PubMed ID: 11134115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle.
    Zambrano E; Olivares A; Mendez JP; Guerrero L; Díaz-Cueto L; Veldhuis JD; Ulloa-Aguirre A
    J Clin Endocrinol Metab; 1995 May; 80(5):1647-56. PubMed ID: 7745013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone and dihydrotestosterone, but not estradiol, selectively maintain pituitary and serum follicle-stimulating hormone in gonadotropin-releasing hormone antagonist treated male rats.
    Arslan M; Weinbauer GF; Khan SA; Nieschlag E
    Neuroendocrinology; 1989 Apr; 49(4):395-401. PubMed ID: 2497399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed puberty in males with beta-thalassemia major: pulsatile gonadotropin-releasing hormone administration induces changes in gonadotropin isoform profiles and an increase in sex steroids.
    Valenti S; Giusti M; McGuinness D; Guido R; Mori PG; Giordano G; Dahl KD
    Eur J Endocrinol; 1995 Jul; 133(1):48-56. PubMed ID: 7627337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
    Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
    J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment.
    Swerdloff RS; Handelsman DJ; Bhasin S
    J Steroid Biochem; 1985 Nov; 23(5B):855-61. PubMed ID: 2934582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin subunit messenger RNA concentrations after blockade of gonadotropin-releasing hormone action: testosterone selectively increases follicle-stimulating hormone beta-subunit messenger RNA by posttranscriptional mechanisms.
    Paul SJ; Ortolano GA; Haisenleder DJ; Stewart JM; Shupnik MA; Marshall JC
    Mol Endocrinol; 1990 Dec; 4(12):1943-55. PubMed ID: 1707128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vitamin A deficiency upon gonadotropin response to gonadotropin-releasing hormone.
    Huang HS; Dyrenfurth I; Gunsalus GL; Hembree WC
    Biol Reprod; 1985 Dec; 33(5):1176-87. PubMed ID: 3935184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.